You are not currently logged in.
Access JSTOR through your library or other institution:
Efficacy and Safety of Low-Dose Aztreonam in the Treatment of Moderate to Severe Infections Due to Gram-Negative Bacilli
Alain Clergeot, Dominique Steru, Marie-Anne Rosset and Claude Carbon
Reviews of Infectious Diseases
Vol. 13, Supplement 7. Aztreonam: The Expanding Clinical Profile (May - Jun., 1991), pp. S648-S651
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4456016
Page Count: 4
You can always find the topics here!Topics: Infections, Antibiotics, Dosage, Superinfection, Administered dose, Symptomatology, Health outcomes, Sepsis, Urinary tract infections, Community acquired infections
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
One hundred fifty-three patients with moderate to severe infections due to gram-negative bacilli, including septicemia (60 cases), lower respiratory tract infection (32 cases), intraabdominal infection (40 cases), and urinary tract infection (21 cases), were treated with aztreonam (1 g every 12 h). This dosage is lower than usual. Criteria for inclusion in the study included documented infection due to gram-negative bacilli and a measurement of severity of disease of <12 (as defined by a Simplified Acute Physiology Score for the 115 cases of community-acquired infection) or ≤1 (as defined by an Organ System Failure Score for 38 cases of nosocomial infection). Other than aztreonam, no antibiotic active against gram-negative bacilli was allowed to be used for treatment. Seventy-one patients in whom gram-positive or anaerobic organisms were detected or suspected were given additional agents effective against the organisms. One hundred forty-one patients (92.2%) were cured; the mean duration of treatment was 10.9 ± 4.0 days. None of the gram-negative bacilli initially isolated became resistant to aztreonam. Colonization, generally by a gram-positive organism, was observed in 27 patients and superinfection was observed in five. Aztreonam was well tolerated. This study suggests that a dosage of 2 g daily of aztreonam should be appropriate in the treatment of moderate to severe infections due to susceptible gram-negative bacilli.
Reviews of Infectious Diseases © 1991 Oxford University Press